Thursday 16 October, 2025
Objectives: The most common malignancy in middle and older aged men worldwide is prostate cancer (PCa).1 Characteristic for PCa is a…
Read moreAbstracts
Enabling Tyrosine Kinase Inhibitor Precision Medicine through PET-Guided Physiologically-Based Pharmacokinetic Modeling
Thursday 16 October, 2025
Objectives: Osimertinib, a tyrosine kinase inhibitor (TKI), is used in treating non-small cell lung cancer (NSCLC) with epidermal growth factor…
Read moreEarly morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study
Thursday 16 October, 2025
Objectives: Anticancer drug administration timing may greatly affect patient’s survival, response and toxicities (1, 2). This time-of-day variability originates from…
Read moreQuantitative Systems Pharmacology to Personalize Temozolomide-based Drug Combinations against Brain Tumors.
Thursday 16 October, 2025
Objectives: Large inter-patient heterogeneity in anticancer drug response highlights the critical need for personalized cancer management which has favored the…
Read moreEstablishment of Virtual Bioequivalence via DoE-PBPM Model: A Donepezil Case Study
Thursday 16 October, 2025
Objectives: Donepezil (DZP) is a medication used to treat Alzheimer’s disease. It works by inhibiting the breakdown of acetylcholine in…
Read moreAn automated multi-model selection algorithm to improve precision dosing of tacrolimus in liver, lung, and bowel transplant recipients
Thursday 16 October, 2025
Objectives: Tacrolimus is a cornerstone immunosuppressant for preventing graft rejection after solid organ transplantation. It is characterized by highly variable…
Read moreModel-informed intravenous-to-subcutaneous switching of infliximab in patients with inflammatory bowel diseases
Thursday 16 October, 2025
Objectives: Infliximab, the pioneering anti-tumor necrosis factor (TNF) monoclonal antibody, transformed the treatment landscape for inflammatory bowel diseases. Twenty-five years…
Read moreTarget engagement analysis of belimumab in patients with systemic lupus erythematosus (SLE) and primary Sjogren’s syndrome (pSS)
Thursday 16 October, 2025
Introduction: Elevated B-lymphocyte stimulator (BLyS) levels are found in B-cell-mediated autoimmune diseases such as SLE and pSS[1,2]. Belimumab (BEL) inhibits…
Read moreOptimization of dosing strategy for vancomycin using a population pharmacokinetic model combined with machine learning approaches
Thursday 16 October, 2025
Objectives: The optimized dose and frequency of dosing for vancomycin are critical to achieve target AUC and trough concentrations at…
Read moreBayesian framework for multi-source data integration – application to Human extrapolation from preclinical studies
Thursday 16 October, 2025
Introduction: In preclinical research, including in vitro studies (conducted within subcellular fractions, cell cultures, micro-organisms, organoid models, etc.), in vivo…
Read more